Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Letter to the Editor

Functional cure of chronic hepatitis B encounters resmetirom

Nai-Bin Yang, Wai-Kay Seto, Ming-Hua Zheng

Clin Mol Hepatol. 2024;30(3):580-581. Published online April 30, 2024

DOI: https://doi.org/10.3350/cmh.2024.0301

View: 864 Download: 71

Changing from NAFLD to MASLD: Prevalence and progression of ASCVD risk are similar between NAFLD and MASLD in Asia

Hiroyuki Suzuki, Tsubasa Tsutsumi, Machiko Kawaguchi, Keisuke Amano, Takumi Kawaguchi

Clin Mol Hepatol. 2024;30(3):577-579. Published online March 6, 2024

DOI: https://doi.org/10.3350/cmh.2024.0157

View: 1160 Download: 117 Crossref: 2

Letter regarding “Hepatitis B core-related antigen dynamics and risk of subsequent clinical relapses after nucleos(t)ide analog cessation”

Yun-Fan Liaw

Clin Mol Hepatol. 2024;30(2):269-271. Published online January 31, 2024

DOI: https://doi.org/10.3350/cmh.2024.0064

View: 1601 Download: 32 Web of Science: 1 Crossref: 1

Tsubasa Tsutsumi, Dan Nakano, Machiko Kawaguchi, Hirokazu Takahashi, Takumi Kawaguchi

Clin Mol Hepatol. 2024;30(2):266-268. Published online January 30, 2024

DOI: https://doi.org/10.3350/cmh.2024.0028

View: 1766 Download: 42 Crossref: 1

Changing from NAFLD to MASLD: Similar prognosis of patients with HCC under atezolizumab/bevacizumab treatment between NAFLD and MASLD

Hiroyuki Suzuki, Shigeo Shimose, Hideki Iwamoto, Takashi Niizeki, Takumi Kawaguchi

Clin Mol Hepatol. 2024;30(2):263-265. Published online January 18, 2024

DOI: https://doi.org/10.3350/cmh.2023.0557

View: 2128 Download: 123 Web of Science: 4 Crossref: 5

Changing from NAFLD to MASLD: Similar cumulative incidence of reflux esophagitis between NAFLD and MASLD

Shuhei Fukunaga, Michita Mukasa, Dan Nakano, Tsubasa Tsutsumi, Takumi Kawaguchi

Clin Mol Hepatol. 2024;30(1):121-123. Published online December 4, 2023

DOI: https://doi.org/10.3350/cmh.2023.0437

View: 1674 Download: 73 Web of Science: 6 Crossref: 7

Letter regarding “Waiting for the changes after the adoption of steatotic liver disease”

Kuo Chao Yew, Sunny H. Wong, Vincent Wai-Sun Wong, Hazel H. Oon

Clin Mol Hepatol. 2024;30(1):118-120. Published online November 14, 2023

DOI: https://doi.org/10.3350/cmh.2023.0472

View: 1954 Download: 49 Web of Science: 2 Crossref: 1

Letter 2 regarding “Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma”

Yiwen Zhang, Liwei Wu, Zepeng Mu, Linlin Ren, Ying Chen, Hanyun Liu, Lili Xu, Yangang Wang, Yaxing Wang, Susan Cheng, Yih Chung Tham, Bin Sheng, Tien Yin Wong, Hongwei Ji

Clin Mol Hepatol. 2024;30(1):113-117. Published online November 10, 2023

DOI: https://doi.org/10.3350/cmh.2023.0440

View: 1746 Download: 67 Web of Science: 2 Crossref: 1

Letter 1 regarding “Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma”

Hinpetch Daungsupawong, Viroj Wiwanitkit

Clin Mol Hepatol. 2024;30(1):111-112. Published online October 13, 2023

DOI: https://doi.org/10.3350/cmh.2023.0394

View: 1625 Download: 52

Letter regarding “Treated chronic hepatitis B is a good prognostic factor of diffuse large B-cell lymphoma”

Chi Hsiao, Yung-Po Liaw

Clin Mol Hepatol. 2024;30(1):109-110. Published online October 11, 2023

DOI: https://doi.org/10.3350/cmh.2023.0373

View: 1394 Download: 35

Letter regarding “Risk factors in nonalcoholic fatty liver disease”

Abhijit Pratap, Umesh More, Pradnya Phalak, Anita Deshmukh

Clin Mol Hepatol. 2023;29(4):1046-1047. Published online August 22, 2023

DOI: https://doi.org/10.3350/cmh.2023.0268

View: 1691 Download: 40 Web of Science: 1 Crossref: 1

Letter regarding “Evidence-based hyponatremia management in liver disease”

Daphne J. Theodorou, Stavroula J. Theodorou, Ioannis V. Mitselos

Clin Mol Hepatol. 2023;29(4):1043-1045. Published online July 5, 2023

DOI: https://doi.org/10.3350/cmh.2023.0204

View: 1883 Download: 35 Crossref: 1

Letter 2 regarding “Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma”

Amnuay Kleebayoon, Viroj Wiwanitkit

Clin Mol Hepatol. 2023;29(3):815-816. Published online May 24, 2023

DOI: https://doi.org/10.3350/cmh.2023.0170

View: 2086 Download: 57 Web of Science: 2 Crossref: 1

Letter 1 regarding “Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma”

Hassam Ali

Clin Mol Hepatol. 2023;29(3):813-814. Published online May 19, 2023

DOI: https://doi.org/10.3350/cmh.2023.0120

View: 2166 Download: 67 Web of Science: 1

Letter regarding “Is liver biopsy essential to identifying the immune tolerant phase of chronic hepatitis B?”

Halil Haldun Emiroglu

Clin Mol Hepatol. 2023;29(3):812-812. Published online May 8, 2023

DOI: https://doi.org/10.3350/cmh.2023.0132

View: 1870 Download: 25

Letter regarding “Non-alcoholic fatty liver disease: Definition and subtypes”

Seogsong Jeong, Yohwan Lim, Su Kyoung Lee, Hyun Wook Han

Clin Mol Hepatol. 2023;29(3):810-811. Published online May 8, 2023

DOI: https://doi.org/10.3350/cmh.2023.0129

View: 2094 Download: 60 Web of Science: 1

Letter regarding “Long-term prognosis and the need for histologic assessment of chronic hepatitis B in the serological immune-tolerant phase”

Chia-Ming Chu, Yun-Fan Liaw

Clin Mol Hepatol. 2023;29(2):510-512. Published online January 30, 2023

DOI: https://doi.org/10.3350/cmh.2023.0018

View: 2448 Download: 68 Web of Science: 1 Crossref: 1

Correspondence on Letter regarding “The usefulness of metabolic score for insulin resistance for the prediction of incident non-alcoholic fatty liver disease in Korean adults”

Jun-Hyuk Lee, Kyongmin Park, Hye Sun Lee, Hoon-Ki Park, Jee Hye Han, Sang Bong Ahn

Clin Mol Hepatol. 2023;29(1):179-181. Published online November 22, 2022

DOI: https://doi.org/10.3350/cmh.2022.0409

View: 2789 Download: 46 Web of Science: 1 Crossref: 1

Correspondence on Letter regarding “COVID-19 vaccine immunogenicity among chronic liver disease patients and liver transplant recipients: A meta-analysis”

Ka Shing Cheung, Chiu Hang Mok, Wai Kay Seto, Man Fung Yuen

Clin Mol Hepatol. 2023;29(1):176-178. Published online November 10, 2022

DOI: https://doi.org/10.3350/cmh.2022.0377

View: 2758 Download: 51

Correspondence on Letter regarding “Impacts of muscle mass dynamics on prognosis of outpatients with cirrhosis”

Tae Hyung Kim, Young Kul Jung, Hyung Joon Yim

Clin Mol Hepatol. 2023;29(1):173-175. Published online November 15, 2022

DOI: https://doi.org/10.3350/cmh.2022.0372

View: 2872 Download: 44 Web of Science: 1 Crossref: 1

Correspondence on Letter regarding “Auranofin attenuates hepatic steatosis and fibrosis in nonalcoholic fatty liver disease via NRF2 and NF-κB signaling pathways”

Seung Min Lee, Dae Won Jun

Clin Mol Hepatol. 2023;29(1):171-172. Published online November 10, 2022

DOI: https://doi.org/10.3350/cmh.2022.0381

View: 2828 Download: 56

Letter regarding “The usefulness of metabolic score for insulin resistance for the prediction of incident non-alcoholic fatty liver disease in Korean adults”

Hye Won Lee

Clin Mol Hepatol. 2023;29(1):169-170. Published online November 10, 2022

DOI: https://doi.org/10.3350/cmh.2022.0384

View: 3051 Download: 50 Web of Science: 1 Crossref: 1

Letter regarding “COVID-19 vaccine immunogenicity among chronic liver disease patients and liver transplant recipients: A meta-analysis”

Rujittika Mungmunpuntipantip, Viroj Wiwanitkit

Clin Mol Hepatol. 2023;29(1):168. Published online October 31, 2022

DOI: https://doi.org/10.3350/cmh.2022.0328

View: 2868 Download: 53 Web of Science: 1 Crossref: 1

Letter regarding “Impacts of muscle mass dynamics on prognosis of outpatients with cirrhosis”

Do Seon Song, U Im Chang, Jin Mo Yang

Clin Mol Hepatol. 2023;29(1):165-167. Published online October 31, 2022

DOI: https://doi.org/10.3350/cmh.2022.0339

View: 3388 Download: 61 Web of Science: 1 Crossref: 1

Letter regarding “Auranofin attenuates hepatic steatosis and fibrosis in nonalcoholic fatty liver disease via NRF2 and NF-κB signaling pathways”

Yuanbin Liu, Mingkai Chen

Clin Mol Hepatol. 2023;29(1):163-164. Published online October 27, 2022

DOI: https://doi.org/10.3350/cmh.2022.0326

View: 3203 Download: 61 Web of Science: 1 Crossref: 1

Non-alcoholic fatty liver disease and risk of dementia: Unmet need for a pooled analysis of cohort studies

Seogsong Jeong, Won Kim, Sang Min Park

Clin Mol Hepatol. 2022;28(4):933-934. Published online September 14, 2022

DOI: https://doi.org/10.3350/cmh.2022.0267

View: 2964 Download: 66

Non-alcoholic fatty liver disease and the risk of dementia: A meta-analysis of cohort studies

Li-Yu Lu, Min-You Wu, Yung-Shuo Kao, Cheng-Hsien Hung

Clin Mol Hepatol. 2022;28(4):931-932. Published online September 5, 2022

DOI: https://doi.org/10.3350/cmh.2022.0259

View: 2984 Download: 102 Web of Science: 7 Crossref: 6

Forms of cholangitis to be considered after SARS-CoV-2 infection

Ju-Yeon Cho, Young-Sun Lee, Soon Sun Kim, Do Seon Song, Jeong-Hoon Lee, Ji Hoon Kim

Clin Mol Hepatol. 2022;28(4):929-930. Published online September 8, 2022

DOI: https://doi.org/10.3350/cmh.2022.0260

View: 2425 Download: 58 Web of Science: 2 Crossref: 3

Autoimmune liver disease represented as primary biliary cholangitis after SARS-CoV-2 infection: A need for population-based cohort study

Soon Kyu Lee, Jung Hyun Kwon, Nara Yoon, Soon Woo Nam, Pil Soo Sung

Clin Mol Hepatol. 2022;28(4):926-928. Published online September 5, 2022

DOI: https://doi.org/10.3350/cmh.2022.0233

View: 2561 Download: 73 Web of Science: 2 Crossref: 3

Clinical significance of the discrepancy between radiological findings and biochemical responses in atezolizumab plus bevacizumab for hepatocellular carcinoma

Hideki Iwamoto, Shigeo Shimose, Takashi Niizeki, Hironori Koga, Takuji Torimura

Clin Mol Hepatol. 2022;28(3):575-579. Published online April 21, 2022

DOI: https://doi.org/10.3350/cmh.2022.0047

View: 3451 Download: 206 Web of Science: 6 Crossref: 6

Viewed By 5661	MAFLD: How is it different from NAFLD?
Viewed By 5579	Prognostic value of ultra-low-pass whole-genome sequencing of circulating tumor DNA in hepatocellular carcinoma under systemic treatment
Viewed By 5384	Evaluating the therapeutic efficacy of NAD supplementation in management of metabolic dysfunction-associated steatotic liver disease: Key considerations
Viewed By 5332	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Viewed By 4984	Global incidence and prevalence of nonalcoholic fatty liver disease

Cited By 176	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Cited By 119	Global incidence and prevalence of nonalcoholic fatty liver disease
Cited By 113	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Cited By 91	MAFLD: How is it different from NAFLD?
Cited By 82	Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical bayesian approach

Letter to the Editor